1. European Lung Cancer Working Party (ELCWP) : Les recommandations de pratique clinique de l’European Lung Cancer Working Party. Cancers bronchiques non à petites cellules : III. Maladies avancées (métastatiques). Rev Med Brux 2007 ; 28 : 495-511.
2. Gralla RJ, Casper ES, Kelsen DP, Braun DWJ, Dukeman ME, Martini N, Young CW, Golbey RB : Cisplatin and vindesine combination chemotherapy for advanced carcinoma of the lung : a randomized trial investigating two dosage schedules. Ann Intern Med 1981 ; 95 : 414-20.
3. Klastersky J, Sculier JP, Ravez P, Libert P, Michel J, Vandermoten G, Rocmans P, Bonduelle Y, Mairesse M, Michiels T : A randomized study comparing a high and a standard dose of cisplatin in combination with etoposide in the treatment of advanced non-small-cell lung carcinoma. J Clin Oncol 1986 ; 4 : 1780-6.
4. Shinkai T, Saijo N, Eguchi K, Sasaki Y, Tominaga K, Sakurai M, Suga J, Miyaoka H, Sano T, Keicho N : Cisplatin and vindesine combination chemotherapy for non-small cell lung cancer : a randomized trial comparing two dosages of cisplatin. Jpn J Cancer Res 1986 ; 77 : 782-9.
5. Gandara DR, Crowley J, Livingston RB, Perez EA, Taylor CW, Weiss G, Neefe JR, Hutchins LF, Roach RW, Grunberg SM : Evaluation of cisplatin intensity in metastatic non-small-cell lung cancer : a phase III study of the Southwest Oncology Group. J Clin Oncol 1993 ; 11 : 873-8.